US FDA Continues Its Goal of Propelling Model-Based Drug Development Forward

Simulations Plus Announces Employee Bonuses
Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development, today announced that it will be distributing a one-time $1,000 discretionary cash bonus to each of its employees.

Simulations Plus, Inc. to Host Earnings Call
Simulations Plus, Inc. (NASDAQ: SLP) will be discussing their earnings results in their Q2 Earnings Call to be held on April 9, 2018, at 4:15 PM Eastern Time.

Simulations Plus Reports Record Second Quarter FY2018 Revenue
Board of Directors Announces Quarterly Dividend of $0.06 Per Share

Data Projects Medical Technologies Market to Expand
FinancialBuzz.com News Commentary

Simulations Plus Launches Version 2.0 of PKPlus™
Major update to preclinical and clinical trial data analysis software addresses user requests

DILIsym Services Inc., a Simulations Plus Company, Releases DILIsym® Version 7A
Significant update of liver safety program includes performance and capability enhancements

Simulations Plus Reports First Quarter FY2018 Financial Results
Consolidated net income up 26.0%; diluted earnings per share increased 22.8%

Simulations Plus Sets Date for 1st Quarter 2018 Earnings Release and Conference Call
Conference Call to be on Tuesday, January 9, 2018, at 4:15 PM ET

Wildfire Forces Cancelation of LD Micro Conference
Presentations Canceled for Celsius Holdings, Inc., GSI Technology, Inc., PCM, Inc., Simulations-Plus, ADOMANI, Inc., HUTN, Inc., NanoVibronix, Inc. and WidePoint Corp.

Simulations Plus Releases ADMET Predictor™ Version 8.5
New HTPK Simulation Module allows chemists to screen compound libraries using novel approach

Simulations Plus Reports FY2017 and Fourth Quarter FY2017 Financial Results
Full Fiscal Year Pharmaceutical Software and Services Revenues Up 20.9%;
Earnings per share of $0.33, up 14.9% over prior year

Simulations Plus Reports Preliminary Revenues for Fourth Quarter and Fiscal Year 2017
Company Reports Record Fourth-Quarter and Full-Year Revenues